Bioidea Group

Bioidea Group jointly produced the latest Longevity 200 event at Harvard Club NYC (https://lnkd.in/e7jewRMG), featuring an intriguing presentation from Resonance Therapeutics on "AI, Resonance-Based Health Enhancement and Longevity Achievement." The company shared a compelling approach exploring the intersection of quantum mechanics, artificial intelligence, and bioresonance - examining how precisely calibrated external frequency interventions might interact with biological systems. Scientific Considerations: - Quantum mechanics approach to understanding cellular vibrations - AI-driven analysis of complex biological resonance patterns - Potential methodologies for frequency-based health modulation While the methodology requires rigorous validation, it highlights emerging directions at the intersection of quantum physics, computational biology, and longevity science. Our ongoing event series continues to spotlight cutting-edge research with potential transformative implications for human health. Special thanks to Ludicrous Ventures TM' , Sergei Petukhov, Walter Olesiak #longevity #aging #innovation

BIO CEO Conference 2025 - attended this year's BIO CEO gathering. We're seeing incredible advances in obesity treatments, AI-powered drug discovery, and immunotherapies that would have seemed like science fiction just a few years ago. - Attendance from larger pharmaceutical companies and institutional investors was notably subdued - Scientific innovation is alive and kicking - Investor confidence remains tentative, reflecting a "quality over quantity" approach to biotechnology investments - Specialist investors continue to dominate, with generalist participation still on the sidelines - The days of throwing money at every promising idea are over In this market, it's not just about having a great idea. It's about execution, proof, and showing real potential. The teams that can demonstrate clear, compelling value will be the ones to watch.

Delighted to share that our Bioidea Group founder and partner, Dr. Borys Shor, delivered a compelling presentation at last week's Harvard Club of NYC's exclusive Longevity Group seminar. His talk on "From Cancer Research to Longevity Medicine: Understanding Core Aging Pathways" sparked engaging discussions on the intersection of oncology research and aging biology. Drawing from his extensive experience leading drug discovery programs at Pfizer and Wyeth, Dr Shor shared valuable insights on how cancer research pathways are informing the next frontier of longevity medicine. This speaking engagement at the Harvard Club aligns perfectly with Bioidea Group's mission of accelerating life-changing discoveries in healthcare. As we continue to connect promising biotech innovations with strategic capital in NYC's thriving ecosystem, our leadership's involvement in these high-level discussions helps shape the future of therapeutic development. Special thanks to Ludicrous Ventures TM' founder Sergei Petukhov for contributing valuable insights on microbiome innovations in longevity science. We're grateful to the head of the Longevity Group SIG for organizing this important event, and to the Harvard Club of New York City for hosting this meaningful dialogue. #Biotech #Longevity #Cancer

Fall Update: The Bioidea Group team recently completed an intensive conference circuit across NYC's premier life sciences investment events: Life Sciences Summit (Oct 8-9) | Alexandria Center: A phenomenal gathering bringing together 300+ biotech leaders, where we participated in crucial discussions on precision medicine development, creative financing structures, and strategic deal-making in the current market environment. Particularly valuable were the insights from pharma leaders and investors on bioconvergence platforms and next-gen therapeutic approaches. Special thanks to the Center for Biotechnology, NYS Center for Advanced Technology team — Diane Fabel, Kate Hutchinson, Anne DePietri, CRA Dee Dao, and Clinton Rubin—for orchestrating this impactful event. https://lnkd.in/ekrbfaG BioFuture #BioFuture2024 (Oct 28-30): Three days of deep dives into transformative technologies reshaping our industry, from AI-driven drug discovery to bioelectronic medicine and novel cell & gene therapy platforms. The convergence of technology and biology was a central theme, highlighting significant opportunities for strategic investment and partnership. Many thanks to Sara Jane Demy and the Demy-Colton team for bringing together such an exceptional gathering of industry leaders. https://lnkd.in/ecezR7TY ThinkEquity Conference (Oct 30) | Mandarin Oriental: Connected with innovative public and private healthcare companies, focusing on emerging therapeutic modalities and novel technology platforms. The breadth of presenting companies offered unique insights into market dynamics across various therapeutic areas. Appreciation to ThinkEquity's experienced investment banking team for curating a diverse roster of presenting companies. Joe Jaigobind Eric Lord Tara Sharif ThinkEquity LLC https://lnkd.in/eBN5YWUj Spartan Capital Investor Conference (Nov 4) | The Pierre Hotel: Rounded out our fall conference season with focused discussions on market trends and investment strategies in the life sciences sector, particularly valuable for understanding the evolving funding landscape for emerging biotech companies. Thanks to the Spartan Capital Securities, LLC team and B2i Digital for organizing this premier event ! https://lnkd.in/eN2Hzz6T These forums reinforced our conviction in several key investment themes for 2025 and beyond, while strengthening our network of industry relationships. Looking forward to leveraging these insights to continue supporting innovative companies advancing breakthrough science. #LifeSciences #Biotech #Investment #NYCBiotech

We're excited to share that our founder and partner, Dr. Borys Shor, attended the NYSE American listing ceremony for OS Therapies (NYSE-A: OSTX) yesterday. As an advisor to OSTX, Dr. Shor had the privilege of witnessing the culmination of years of dedication and hard work by the entire OSTX team. The ceremony, held on the NYSE American trading floor and skillfully coordinated by Paul Dorfman, Head of Listings at NYSE American, marked OSTX's debut as a publicly traded company. It was inspiring to see CEO Paul Romness, CBO Gerald Commissiong, and the Board of Directors ring the bell, symbolizing not just the start of OSTX's public company journey, but also the potential of their innovative work in developing treatments for osteosarcoma and other solid tumors. We were also glad to see Tingting Zhang-Kharas, PhD, Head of JLABS US Northeast, Johnson & Johnson Innovation, joining the ceremony. Her presence highlighted OSTX's recent acceptance into JLabs NYC - a testament to their innovative approach in developing treatments for osteosarcoma and other solid tumors. We at Bioidea Group are proud to be associated with such groundbreaking work in the biotech sector. The unwavering commitment of the OSTX team to improving patient outcomes is truly commendable. Congratulations to Paul, Gerald, the Board, and the entire OS Therapies team on this remarkable achievement! We look forward to following OSTX's progress as they continue to advance their clinical programs and work towards transforming cancer treatment. #Biotech #IPO #NYSEAmerican #CancerResearch #OSTherapies

Bioidea Group was honored to participate in the ACG NY Family Office & Limited Partner Series - Summer Soiree yesterday at The Vaults, 40 Wall Street, New York City. This exclusive event, organized by the Association for Corporate Growth (ACG), brought together key players in the investment and entrepreneurship ecosystem. The evening featured an enlightening fireside chat on the 'Journey from Start to Serial Entrepreneur' with speaker Michele Valad?o Levy, Founder and CEO of Ilhabela Holdings and Co-Founder and CEO, Costa Brazil, moderated by Sasha Bernier, Managing Partner at Hestia Holdings LLC, Managing Director at Cheltenham Enterprises. As a group dedicated to accelerating impact in biotech and life sciences, we found immense value in networking with fellow innovators, investors, and industry experts. ACG's global network, operating in 61 local markets worldwide and comprising over 100,000 middle market professionals, provides an ideal platform for fostering connections that can drive growth in our sector. We're grateful to ACG New York, lead partner CohnReznick LLP, and partners UHY LLP, Certified Public Accountants and Family Office Association for organizing this high-caliber event. Special thanks to the ACG New York Family Office Committee for hosting. These connections will undoubtedly help us further support groundbreaking advancements in healthcare and life sciences. We look forward to leveraging these new relationships to drive innovation and investment in our field. #familyoffices #heatlhcare #innovation #nyc With Borys S. Sergei Petukhov Ludicrous Ventures TM Liza Garber James Howe Jason Hornung Angela Wong, CPA, MST Jeanine Marino, CPA

We attended the NewYorkBIO's 2024 Finance Summit at West End Labs, NYC. The summit provided valuable insights into current investment trends and funding opportunities in life sciences. We're excited to leverage these connections to continue bridging promising healthcare companies with potential investors. Special thanks to Matthew Malone, SVP of Life Science at Elevate Research Properties, for the informative tour of West End Labs. Looking forward to exploring new partnerships and presenting innovative healthcare solutions to our investor network. We had the pleasure of meeting Tim Opler, Managing Director of Biopharma at Stifel, who shared his wisdom on strategic and financing transactions in healthcare. #biotech #healthcare #investments #NYC

We attended the NewYorkBIO's 2024 Finance Summit at West End Labs, NYC. The summit provided valuable insights into current investment trends and funding opportunities in life sciences. We're excited to leverage these connections to continue bridging promising healthcare companies with potential investors. Special thanks to Matthew Malone, SVP of Life Science at Elevate Research Properties, for the informative tour of West End Labs. Looking forward to exploring new partnerships and presenting innovative healthcare solutions to our investor network. We had the pleasure of meeting Tim Opler, Managing Director of Biopharma at Stifel, who shared his wisdom on strategic and financing transactions in healthcare. #biotech #healthcare #investments #NYC

Bioidea Group was honored to participate in the AWS x PTP NY #TechWeek Boat Cruise for Biotech Startups. This event brought together a select group of biotech innovators, industry leaders, and investors to discuss the latest advancements in AI-driven healthcare solutions. We were excited to engage with entrepreneurs who are leveraging cutting-edge technologies to tackle critical healthcare challenges. The event provided a unique opportunity to evaluate promising investment opportunities and forge strategic connections to drive these innovations forward. Throughout the evening, we had productive conversations with several companies at the forefront of AI-powered diagnostics, precision medicine, and drug discovery. Their dedication to improving patient outcomes and revolutionizing healthcare delivery was truly inspiring. We appreciate the efforts of Amazon Web Services (AWS) and PTP in organizing this valuable event and look forward to continuing the dialogue with the inspiring innovators we met. #healthcare #Biotech #Innovation #AWS #PTP #AI

It was great to attend the LifeSci Partners annual cocktail reception in New York last week. The event was an excellent chance to reconnect with friends and colleagues from the biotech and investment community, as well as meet new industry leaders to discuss the latest trends and innovations shaping the future of healthcare. Thanks to the LifeSci Partners team for putting together such a successful event and bringing together people from across the life sciences industry. We're excited about future collaborations and working together to advance groundbreaking solutions in healthcare. Until next year! LifeSci Advisors, LLC LifeSci Communications LifeSci Capital LLC LS Associates LifeSci Venture Partners Ludicrous Ventures TM #health #biotech #innovation #investments